These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

185 related articles for article (PubMed ID: 38447393)

  • 1. PrEP for people who use opioids: A NIDA clinical trials network survey study in Southern U.S. cities where HIV incidence is high.
    Hatch MA; Laschober TC; Paschen-Wolff M; Ertl MM; Nelson CM; Wright L; Lancaster C; Feaster DJ; Forrest D; Hankey C; Monger M; Fegley JP; Irving R; Young C; Rose J; Spector A; Dresser L; Moran L; Jelstrom E; Tross S
    Drug Alcohol Depend; 2024 Apr; 257():111133. PubMed ID: 38447393
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Willingness to use and preferences for long-acting injectable PrEP among sexual and gender minority populations in the southern United States, 2021-2022: cross-sectional study.
    Schoenberg P; Edwards OW; Merrill L; Martinez CA; Stephenson R; Sullivan PS; Jones J
    J Int AIDS Soc; 2023 Mar; 26(3):e26077. PubMed ID: 36951057
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Willingness to take long-acting injectable pre-exposure prophylaxis among men who have sex with men who participated in the CROPrEP study: a cross-sectional online study.
    Liu Y; Chu Z; Wang H; Huang X; Chen Y; Wang H; Zou D; Jiang Y; Geng W; Hu Q; Zhou B; Shang H
    BMC Public Health; 2023 Dec; 23(1):2494. PubMed ID: 38093204
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Willingness to use long-acting injectable PrEP among HIV-negative/unknown men who have sex with men in mainland China: A cross-sectional online survey.
    Fu J; Dai Z; Wang H; Si M; Chen X; Wu Y; Xiao W; Huang Y; Yu F; Mi G; Su X
    PLoS One; 2023; 18(10):e0293297. PubMed ID: 37856527
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Awareness about and willingness to use long-acting injectable pre-exposure prophylaxis (LAI-PrEP) among people who use drugs.
    Shrestha R; DiDomizio EE; Kim RS; Altice FL; Wickersham JA; Copenhaver MM
    J Subst Abuse Treat; 2020 Oct; 117():108058. PubMed ID: 32811633
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Preference for using a variety of future HIV pre-exposure prophylaxis products among men who have sex with men in three US cities.
    Mansergh G; Kota KK; Stephenson R; Hirshfield S; Sullivan P
    J Int AIDS Soc; 2021 Jan; 24(1):e25664. PubMed ID: 33481359
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Awareness of and willingness to use pre-exposure prophylaxis (PrEP) among people who inject drugs and men who have sex with men in India: Results from a multi-city cross-sectional survey.
    Belludi A; McFall AM; Solomon SS; Celentano DD; Mehta SH; Srikrishnan AK; Kumar MS; Solomon S; Lucas GM
    PLoS One; 2021; 16(2):e0247352. PubMed ID: 33630909
    [TBL] [Abstract][Full Text] [Related]  

  • 8. High Interest in Long-acting Injectable Pre-exposure Prophylaxis (LAI-PrEP) for HIV Prevention Among Men Who Have Sex With Men (MSM): Result From A Nationwide Survey in Malaysia.
    Paudel K; Gupta S; Gautam K; Wickersham JA; Khati A; Azwa I; Ha T; Shrestha R
    J Community Health; 2023 Jun; 48(3):513-521. PubMed ID: 36732459
    [TBL] [Abstract][Full Text] [Related]  

  • 9. National trends in HIV pre-exposure prophylaxis awareness, willingness and use among United States men who have sex with men recruited online, 2013 through 2017.
    Sullivan PS; Sanchez TH; Zlotorzynska M; Chandler CJ; Sineath RC; Kahle E; Tregear S
    J Int AIDS Soc; 2020 Mar; 23(3):e25461. PubMed ID: 32153119
    [TBL] [Abstract][Full Text] [Related]  

  • 10. High interest in a long-acting injectable formulation of pre-exposure prophylaxis for HIV in young men who have sex with men in NYC: a P18 cohort substudy.
    Meyers K; Rodriguez K; Moeller RW; Gratch I; Markowitz M; Halkitis PN
    PLoS One; 2014; 9(12):e114700. PubMed ID: 25502768
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Awareness and willingness to use pre-exposure prophylaxis for HIV prevention among men who have sex with men in Rwanda: findings from a web-based survey.
    Munyaneza A; Patel VV; Gutierrez NR; Shi Q; Muhoza B; Kubwimana G; Ross J; Nsereko E; Murenzi G; Nyirazinyoye L; Mutesa L; Anastos K; Adedimeji A
    Front Public Health; 2024; 12():1325029. PubMed ID: 38496393
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Zero knowledge and high interest in the use of long-acting injectable pre-exposure prophylaxis (PrEP) among adolescent men who have sex with men and transgender women in two capital cities in Brazil.
    Pedrana L; Magno L; Zucchi EM; da Silva LAV; Ferraz D; Grangeiro A; Castellanos M; Brasil SA; Dourado I
    BMC Public Health; 2022 Sep; 22(1):1728. PubMed ID: 36096758
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Acceptability of and Preferences for Long-Acting Injectable HIV PrEP and Other PrEP Modalities among Sexual Minority Men in Nigeria, Africa.
    Ogunbajo A; Tsai AC; Kanki PJ; Mayer KH
    AIDS Behav; 2022 Jul; 26(7):2363-2375. PubMed ID: 35061117
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Gearing up for PrEP in the Middle East and North Africa: An Initial Look at Willingness to Take PrEP among Young Men Who Have Sex with Men in Beirut, Lebanon.
    Storholm ED; Mutchler MG; Ghosh-Dastidar B; Balan E; Mokhbat J; Kegeles SM; Wagner GJ
    Behav Med; 2021; 47(2):111-119. PubMed ID: 31851587
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Familiarity with and Preferences for Oral and Long-Acting Injectable HIV Pre-exposure Prophylaxis (PrEP) in a National Sample of Gay and Bisexual Men in the U.S.
    Parsons JT; Rendina HJ; Whitfield TH; Grov C
    AIDS Behav; 2016 Jul; 20(7):1390-9. PubMed ID: 27000145
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Awareness of and Preferences for Preexposure Prophylaxis (PrEP) among MSM at High Risk of HIV Infection in Southern China: Findings from the T2T Study.
    Chen W; Ding Y; Chen J; Zhao P; Wang Z; Meng X; Jia T; Zheng H; Yang B; Luo Z; Zou H
    Biomed Res Int; 2021; 2021():6682932. PubMed ID: 33869634
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Knowledge of and willingness to take pre-exposure prophylaxis among men who have sex with men in Israel.
    Zohar M; Guy S; Itzchak L
    Isr J Health Policy Res; 2021 Dec; 10(1):71. PubMed ID: 34872598
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Increasing awareness of HIV pre-exposure prophylaxis (PrEP) and willingness to use HIV PrEP among men who have sex with men: a systematic review and meta-analysis of global data.
    Sun Z; Gu Q; Dai Y; Zou H; Agins B; Chen Q; Li P; Shen J; Yang Y; Jiang H
    J Int AIDS Soc; 2022 Mar; 25(3):e25883. PubMed ID: 35255193
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Willingness of community-recruited men who have sex with men in Washington, DC to use long-acting injectable HIV pre-exposure prophylaxis.
    Levy ME; Patrick R; Gamble J; Rawls A; Opoku J; Magnus M; Kharfen M; Greenberg AE; Kuo I
    PLoS One; 2017; 12(8):e0183521. PubMed ID: 28827821
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Projected Impact of Expanded Long-Acting Injectable PrEP Use Among Men Who Have Sex With Men on Local HIV Epidemics.
    Balasubramanian R; Kasaie P; Schnure M; Dowdy DW; Shah M; Fojo AT
    J Acquir Immune Defic Syndr; 2022 Oct; 91(2):144-150. PubMed ID: 35636746
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.